Navigation Links
TorreyPines Receives Notice of Delisting from Nasdaq Global Market
Date:7/20/2009

LA JOLLA, Calif., July 20 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) announced today that it had received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market notifying the Company that it did not comply with the minimum $10,000,000 stockholders' equity requirement for continued listing set forth in Listing Rule 5450(b)(1)(A), prior to the expiration of the extension granted by the Staff on July 14, 2009. TorreyPines initially received notification from the Staff of its noncompliance with the minimum $10,000,000 stockholders' equity requirement for continued listing on March 31, 2009.

The Company plans to request a hearing before the Nasdaq Listing Qualifications Panel to review the Staff determination to delist the Company's common stock. The request for a hearing will stay the Staff determination to delist the Company's common stock until the Panel renders a determination following the hearing. The hearing is expected to be scheduled within 30 to 45 days of the Company's request, which the Company will submit on July 21, 2009.

There can be no assurances that the Listing Qualifications Panel will grant the Company's request for continued listing on The Nasdaq Global Market, in which case the Company's common stock could be delisted from The Nasdaq Stock Market.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company which has been committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal has been to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine and
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. TorreyPines Therapeutics Announces its Board of Directors Approval of Plan of Liquidation and Dissolution
2. TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
3. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
4. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
5. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
6. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
7. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
8. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
9. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
10. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
11. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has ... now comes with a second treatment cup to help prevent ... new cup is thinner on the edges for a softer ... thin and uneven surfaces on the face, neck and décolleté. ... treatment on areas such as the cheeks and neck, or ...
(Date:7/10/2014)... PETERSBURG, Russia , July 10, 2014 ... Russian Federation Dmitry Medvedev , presented ... biopharmaceutical company BIOCAD . The Company is developing ... scope of MabNext project BIOCAD develops a number of ... cancer and autoimmune diseases. The ceremony took place at ...
(Date:7/10/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s3bqj2/photonic ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, ... report to their offering. ... photonic integration traces its roots in the latter ... photonic integration went unexplored and unfulfilled for several ...
(Date:7/10/2014)... help in the fight against terrorism with the creation ... explosives with the use of light and special glass ... Actuators B: Chemical , the researchers describe a novel ... as low as 6.3 ppm (parts per million). It ... , "Traditionally explosives detection has involved looking for metals ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Detecting trace amounts of explosives with light 2
... Danaher Corporation (NYSE: DHR ) announced today ... approximately 97% of the currently issued shares of Genetix Group ... dated December 18, 2009. , Danaher intends to acquire any ... acquisition provisions of the applicable UK companies legislation. , ...
... , TSX Exchange Symbol: RVX , Also ... SAN FRANCISCO, CA and CALGARY, Jan. 11 /PRNewswire-FirstCall/ - ... that Donald J. McCaffrey will be presenting at the ... at the Marines, Memorial Club and Hotel in San ...
... , BOSTON, Jan. 11 PAREXEL International ... expectations for the second quarter of Fiscal Year 2010 ended ... ending June 30, 2010. The Company,s updated financial guidance ... business wins and cancellations, revised expectations for the amount and ...
Cached Biology Technology:Danaher Completes Offer for Genetix Group plc 2Resverlogix Presenting at Biotech Showcase 2PAREXEL Issues Updated Financial And Operational Information 2PAREXEL Issues Updated Financial And Operational Information 3PAREXEL Issues Updated Financial And Operational Information 4PAREXEL Issues Updated Financial And Operational Information 5
(Date:7/11/2014)... Recent evidence has demonstrated that transplantation of mesenchymal stem ... rat or mouse models of Alzheimer,s disease (AD) and ... cerebral ischemia. Few studies are reported on the therapeutic ... with AD and on the effect on oxidative injury ... Yufang Yan and her team, School of Life Sciences, ...
(Date:7/11/2014)... proteins that let nerve cells send out electrical signals, ... biological tactic that may offer a new way to ... environmentally responsible way. , Their findingthat naturally occurring ... harmless for a closely related onesuggests that insecticides can ... species like bees. A summary of the research, led ...
(Date:7/10/2014)... 2014  Aware, Inc. (NASDAQ: AWRE ), ... announced on June 26, 2014 that its Board of ... per share, or approximately $40 million in total.  The ... and a payment date of July 24, 2014.  The ... set an ex-dividend date for this special cash dividend. ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... only multi drug-resistant forms of the disease but could also ... infection as well. Researchers report their results today at ... which this compound is the lead has a very different ... treat tuberculosis. We have identified no cross resistance with ...
... great debate has raged over whether organic compounds and ... meteorite Allan Hills 84001 were processed by living creatures ... been under intense scrutiny ever since. Scientists at the ... fresh look at how material associated with carbonate globules ...
... concerns that hamper embryonic stem cell research, but they still ... with which adult stem cells differentiate into mature tissue the ... impossible for researchers to multiply them in the laboratory. And ... difficult to use them for treating disease. , Now, ...
Cached Biology News:Experimental TB drug effective against resistant and latent mycobacterium tuberculosis 2Relic of life in that Martian meteorite? A fresh look 2Powerful technique for multiplying adult stem cells may aid therapies 2Powerful technique for multiplying adult stem cells may aid therapies 3
One-step, colorimetric, linear detection range 0.7 mg/dL to 300 mg/dL. Procedure: 10 min....
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Recombinant Mouse LIGHT/TNFSF14...
Request Info...
Biology Products: